6 O
ADVERSE O
REACTIONS O
Long-acting O
beta2-adrenergic O
agonists O
, O
such O
as O
STRIVERDI O
RESPIMAT O
, O
increase O
the O
risk O
of O
asthma B-NonOSE_AE
-related O
death B-NonOSE_AE
. O

STRIVERDI O
RESPIMAT O
is O
not O
indicated O
for O
the O
treatment O
of O
asthma B-Not_AE_Candidate
[ O
see O
Boxed O
Warning O
and O
Warning O
and O
Precautions O
( O
5.1 O
) O
] O
. O

EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
incidence O
> O
=2 O
% O
and O
more O
than O
placebo O
) O
are O
nasopharyngitis O
, O
upper O
respiratory O
tract O
infection O
, O
bronchitis O
, O
urinary O
tract O
infection O
, O
cough O
, O
dizziness O
, O
rash O
, O
diarrhea O
, O
back O
pain O
and O
arthralgia O
( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Boehringer O
Ingelheim O
Pharmaceuticals O
, O
Inc O
. O
at O
( O
800 O
) O
542-6257 O
or O
( O
800 O
) O
459-9906 O
TTY O
, O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
in O
Chronic O
Obstructive O
Pulmonary O
Disease O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
with O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
STRIVERDI O
RESPIMAT O
clinical O
development O
program O
included O
seven O
dose-ranging O
trials O
and O
eight O
confirmatory O
trials O
. O

Four O
of O
the O
confirmatory O
trials O
were O
6-week O
cross-over O
trials O
and O
four O
were O
48-week O
parallel O
group O
trials O
. O

Adverse O
reactions O
observed O
in O
the O
dose-ranging O
trials O
and O
four O
6-week O
cross-over O
trials O
were O
consistent O
with O
those O
observed O
in O
the O
48-week O
parallel O
group O
trials O
, O
which O
formed O
the O
primary O
safety O
database O
. O

The O
primary O
safety O
database O
consisted O
of O
pooled O
data O
from O
the O
four O
48-week O
double-blind O
, O
active O
and O
placebo-controlled O
, O
parallel O
group O
confirmatory O
clinical O
trials O
. O

These O
trials O
included O
3104 O
adult O
COPD B-Not_AE_Candidate
patients O
( O
77 O
% O
males O
and O
23 O
% O
females O
) O
40 O
years O
of O
age O
and O
older O
. O

Of O
these O
patients O
, O
876 O
and O
883 O
patients O
were O
treated O
with O
STRIVERDI O
RESPIMAT O
5 O
mcg O
and O
10 O
mcg O
once-daily O
, O
respectively O
. O

The O
STRIVERDI O
RESPIMAT O
groups O
were O
composed O
of O
mostly O
Caucasians O
( O
66 O
% O
) O
with O
a O
mean O
age O
of O
64 O
years O
and O
a O
mean O
percent O
predicted O
FEV1at O
baseline O
of O
44 O
% O
for O
both O
the O
5 O
mcg O
and O
10 O
mcg O
treatment O
groups O
. O

Control O
arms O
for O
comparison O
included O
placebo O
in O
all O
four O
trials O
plus O
formoterol O
12 O
mcg O
in O
two O
trials O
. O

In O
these O
four O
clinical O
trials O
, O
seventy-two O
percent O
( O
72 O
% O
) O
of O
patients O
exposed O
to O
any O
dose O
of O
STRIVERDI O
RESPIMAT O
reported O
an O
adverse O
reaction O
compared O
to O
71 O
% O
in O
the O
placebo O
group O
. O

The O
proportion O
of O
patients O
who O
discontinued O
due O
to O
an O
adverse O
reaction O
was O
7.2 O
% O
for O
STRIVERDI O
RESPIMAT O
treated O
patients O
compared O
to O
8.8 O
% O
for O
placebo O
treated O
patients O
. O

The O
adverse O
reaction O
most O
commonly O
leading O
to O
discontinuation O
was O
worsening B-OSE_Labeled_AE
COPD I-OSE_Labeled_AE
. O

The O
most O
common O
serious O
adverse O
reactions O
were O
COPD B-OSE_Labeled_AE
exacerbation I-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
, O
and O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
. O

Table O
1 O
shows O
all O
adverse O
drug O
reactions O
reported O
by O
at O
least O
2 O
% O
of O
patients O
( O
and O
higher O
than O
placebo O
) O
who O
received O
STRIVERDI O
RESPIMAT O
5 O
mcg O
during O
the O
48-week O
trials O
. O

Table O
1 O
: O
Number O
and O
frequency O
of O
adverse O
drug O
reactions O
greater O
than O
2 O
% O
( O
and O
higher O
than O
placebo O
) O
in O
COPD O
patients O
exposed O
to O
STRIVERDI O
RESPIMAT O
5 O
mcg O
: O
Pooled O
data O
from O
the O
four O
48-week O
, O
double-blind O
, O
active- O
and O
placebo-controlled O
clinical O
trials O
in O
COPD O
patients O
40 O
years O
of O
age O
and O
older O
* O
Rash B-OSE_Labeled_AE
includes O
a O
grouping O
of O
similar O
terms O
. O

Treatment O
STRIVERDI5 O
mcg O
once-daily O
Placebo O
Body B-NonOSE_AE
system I-NonOSE_AE
( O
adverse O
drug O
reaction O
) O
n=876n O
( O
% O
) O
n=885n O
( O
% O
) O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Nasopharyngitis B-OSE_Labeled_AE
99 O
( O
11.3 O
) O
68 O
( O
7.7 O
) O
Upper B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
72 O
( O
8.2 O
) O
66 O
( O
7.5 O
) O
Bronchitis B-OSE_Labeled_AE
41 O
( O
4.7 O
) O
32 O
( O
3.6 O
) O
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
22 O
( O
2.5 O
) O
9 O
( O
1.0 O
) O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
37 O
( O
4.2 O
) O
35 O
( O
4.0 O
) O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
20 O
( O
2.3 O
) O
19 O
( O
2.1 O
) O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
* O
19 O
( O
2.2 O
) O
10 O
( O
1.1 O
) O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
25 O
( O
2.9 O
) O
22 O
( O
2.5 O
) O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
31 O
( O
3.5 O
) O
24 O
( O
2.7 O
) O
Arthralgia B-OSE_Labeled_AE
18 O
( O
2.1 O
) O
7 O
( O
0.8 O
) O
Additional O
adverse O
reactions O
that O
occurred O
in O
greater O
than O
2 O
% O
( O
and O
higher O
than O
placebo O
) O
of O
patients O
exposed O
to O
STRIVERDI O
RESPIMAT O
10 O
mcg O
were O
pneumonia B-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
and O
pyrexia B-OSE_Labeled_AE
. O

Lung B-OSE_Labeled_AE
cancers I-OSE_Labeled_AE
were O
reported O
in O
6 O
( O
0.7 O
% O
) O
, O
3 O
( O
0.3 O
% O
) O
, O
and O
2 O
( O
0.2 O
% O
) O
patients O
who O
received O
STRIVERDI O
RESPIMAT O
10 O
mcg O
, O
5 O
mcg O
, O
and O
placebo O
, O
respectively O
. O

